scholarly journals Atypical and Rare Forms of Cutaneous Lupus Erythematosus: The Importance of the Diagnosis for the Best Management of Patients

Dermatology ◽  
2021 ◽  
pp. 1-10
Author(s):  
Astrid Herzum ◽  
Giulia Gasparini ◽  
Emanuele Cozzani ◽  
Martina Burlando ◽  
Aurora Parodi
Keyword(s):  
General Practitioner ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Cutaneous Manifestations ◽  
Skin Manifestation ◽  
Systemic Involvement ◽  
Best Management ◽  
Wide Range ◽  
Cutaneous Lupus

Lupus erythematosus (LE) is an autoimmune disease with a wide range of clinical and cutaneous manifestations. Along with the well-known typical cutaneous manifestations of LE, some cutaneous manifestations are rarer, but still characteristic, enabling the dermatologist and the general practitioner who know them to suspect cutaneous LE (CLE) and investigate a possible underlying systemic involvement. Indeed, not infrequently a skin manifestation is the first presentation of systemic LE (SLE), and >75% of SLE patients show signs of skin disease during the course of the illness. Especially, SLE involvement occurs in cases of acute CLE, while it is uncommon in subacute CLE and rare in chronic CLE. This review aims to concentrate especially on atypical cutaneous manifestations of LE to enable the clinician to diagnose even the rarest forms of CLE.

scholarly journals Cutaneous lupus erythematosus, skin or systemic autoimmune disease?

2021 ◽  
Vol 97 (3) ◽  
pp. 120-127
Author(s):  
Bernadett Hidvégi ◽  
◽  
Zsófia Király ◽  
Márta Marschalkó
Keyword(s):  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Systemic Autoimmune Disease ◽  
Cutaneous Manifestations ◽  
Therapeutic Guideline ◽  
Prognostic Relevance ◽  
Clinical Forms ◽  
Cutaneous Lupus

The authors present the different clinical forms of cutaneous lupus erythematosus and their prognostic relevance, along with discusson of the uncommon subtypes of the disease. Furthermore, in addition to the lupus specific cutaneous symptoms, the nonspecific cutaneous manifestations are also reviewed. The newest diagnostic criterias and the EDF therapeutic guideline are summarized.

scholarly journals Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond

2021 ◽  
Vol 2021 ◽  
pp. 1-19
Author(s):  
Elizabeth E. Cooper ◽  
Catherine E. Pisano ◽  
Samantha C. Shapiro
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Cutaneous Lupus Erythematosus ◽  
Laboratory Studies ◽  
Systemic Lupus ◽  
Cutaneous Manifestations ◽  
Distinct Disease ◽  
Cutaneous Lupus

Lupus, Latin for “wolf,” is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes. Cutaneous lupus erythematosus includes a wide array of visible skin manifestations and can progress to systemic lupus erythematosus in some cases. Cutaneous lupus can be subdivided into three main categories: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Physical exam, laboratory studies, and histopathology enable differentiation of cutaneous lupus subtypes. This differentiation is paramount as the subtype of cutaneous lupus informs upon treatment, disease monitoring, and prognostication. This review outlines the different cutaneous manifestations of lupus erythematosus and provides an update on both topical and systemic treatment options for these patients. Other conditions that utilize the term “lupus” but are not cutaneous lupus erythematosus are also discussed.

scholarly journals Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus

Lupus ◽  
2016 ◽  
Vol 26 (6) ◽  
pp. 646-649 ◽  
Author(s):  
E Y Wu ◽  
L E Schanberg ◽  
E C Wershba ◽  
C E Rabinovich
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Retrospective Chart Review ◽  
Rank Test ◽  
Systemic Lupus ◽  
Cutaneous Manifestations ◽  
Prednisone Dose ◽  
Pediatric Systemic Lupus Erythematosus ◽  
Cutaneous Lupus

Objective Cutaneous manifestations of pediatric systemic lupus erythematosus cause significant morbidity. Lenalidomide, a thalidomide analogue, has shown promise treating cutaneous lupus erythematosus in adults. Our objective was to evaluate lenalidomide’s efficacy and safety in treating refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Methods We performed a retrospective chart review of 10 adolescents who received lenalidomide for recalcitrant cutaneous lupus erythematosus. Information was gathered at drug initiation and 6-month follow-up. The Wilcoxon matched-pairs signed-rank test was used to assess change in quantitative parameters of disease activity. Results Nine subjects were girls and six were African-American. Indications for lenalidomide treatment included alopecia, nasal and oral ulcers, extensive malar rash, discoid lesions, bullous lesions, panniculitis, cutaneous vasculitis, and Raynaud’s phenomenon with digital ulcerations. Within 6 months, all patients demonstrated complete or near resolution based on physician report. Prednisone dose decreased from a mean 23.5 mg (SD± 13.3) to 12.25 mg (SD± 9.2) ( P= 0.008). Sedimentation rate decreased from a mean 29 mm/hour (SD± 31.5) to 17 mm/hour (SD± 18.1) ( P= 0.004). Lenalidomide was well tolerated. Conclusion Lenalidomide is an effective and safe treatment for a spectrum of dermatological conditions in pediatric systemic lupus erythematosus. Its use may allow a reduction in prednisone dose and decreased disfigurement. Prospective study is needed to clarify lenalidomide’s role in treating cutaneous manifestations of systemic lupus erythematosus.

scholarly journals Management and obstetric prognosis of pregnancy with isolated cutaneous lupus

2020 ◽  
Vol 11 (e) ◽  
pp. e129.1-e129.4
Author(s):  
Aida Oulehri ◽  
Hanane Baybay ◽  
Soukaina Chhiti
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Fetal Loss ◽  
Insufficient Data ◽  
Systemic Lupus ◽  
Fetal Outcomes ◽  
Systemic Involvement ◽  
Increased Risk ◽  
Cutaneous Lupus

It is well known that pregnancy in a woman with systemic lupus erythematosus (SLE) is associated with an increased risk of adverse maternal and fetal outcomes. But what about the risk in patients with isolated cutaneous lupus erythematosus (CLE) during pregnancy? There are insufficient data on clinical obstetrical and neonatal outcomes in women with CLE and very few studies have been published concerning the obstetric prognosis in the various types of cutaneous lupus. We report the case of a 24-year-old woman with no known pathological history, who presented with a severe and inaugural flare-up of a typical acute lupus erythematosus (ACLE) without systemic involvement which was complicated by a fetal loss.

scholarly journals Linear cutaneous lupus erythematosus in children—report of two cases and review of the literature: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2097920
Author(s):  
Darosa Lim ◽  
Afshin Hatami ◽  
Victor Kokta ◽  
Maryam Piram
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Review Of The Literature ◽  
Inflammatory Lesions ◽  
Systemic Involvement ◽  
Children And Young Adults ◽  
Blaschko’S Lines ◽  
Cutaneous Lupus

Linear cutaneous lupus erythematosus is an unusual presentation of cutaneous lupus following Blaschko’s lines. It is described mostly in children and young adults and is usually not associated with systemic involvement. We report two cases of linear cutaneous lupus erythematosus in children who significantly improved after treatment with hydroxychloroquine in combination with topical corticosteroids and tacrolimus. These rare cases underline the importance of including linear cutaneous lupus erythematosus in the differential diagnosis of blaschkoid inflammatory lesions.

scholarly journals Isoniazid - induced chronic cutaneous Lupus erythematosus

2016 ◽  
Vol 13 (1) ◽  
pp. 52-56
Author(s):  
A Chiriac ◽  
P Brzezinski ◽  
A E Chiriac ◽  
L Foia ◽  
D Mihaila ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Histopathological Examination ◽  
Cutaneous Lupus Erythematosus ◽  
Clinical Aspects ◽  
Direct Immunofluorescence ◽  
Drug Induced ◽  
Systemic Involvement ◽  
Antituberculosis Therapy ◽  
The Face ◽  
Cutaneous Lupus

A 23-year-old man developed drug-induced chronic cutaneous lupus erythematosus 8 months after isoniazid (INH) therapy for pulmonary tuberculosis. Diagnosis was based on clinical aspects (discoid lesions on the face, erythema, photosensitivity, hyperpigmentation), histopathological examination, along with direct immunofluorescence examination (DIF), the absence of systemic involvement and the routine laboratory parameters, which registered all within normal range. Hydroxychloroquine therapy associated to photo protection and emollients determined the clear up of the facial eruption within six months. Transient residual hyperpigmentation could be noticed 2 months after discontinuation of the treatment. This case illustrates a rare form of drug-induced chronic cutaneous lupus erythematosus developed 2 months after withdrawal of antituberculosis therapy, with excellent results with hydroxychloroquine.NJDVL Vol. 13, No. 1, 2015 Page: 52-56

Sign in / Sign up

Export Citation Format

Share Document